Combining Chemotherapy with IL-18 for Better Cancer Treatment
Author Information
Author(s): Ioannis Alagkiozidis, Andrea Facciabene, Marinos Tsiatas, Carmine Carpenito, Fabian Benencia, Sarah Adams, Zdenka Jonak, Carl H June, Daniel J Powell Jr, George Coukos
Primary Institution: University of Pennsylvania
Hypothesis
Time-dependent chemotherapy drugs are more likely to benefit from combination with immune therapy.
Conclusion
Tumor immunotherapy with IL-18 can significantly augment the killing fraction of phase-specific chemotherapeutic drugs and provide survival benefit.
Supporting Evidence
- IL-18 significantly restricted ascites accumulation in tumor-bearing mice.
- Combination therapy with IL-18 and paclitaxel prolonged median survival by 59%.
- IL-18 alone prolonged median survival by 17%.
Takeaway
This study shows that using a special immune booster called IL-18 with certain cancer drugs can help kill more cancer cells and make patients live longer.
Methodology
The study tested four chemotherapy drugs in vitro and in vivo with IL-18 to assess their effectiveness against ovarian cancer cells.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website